<DOC>
	<DOCNO>NCT02123368</DOCNO>
	<brief_summary>Purpose : To determine safety , feasibility effectiveness ( clinical radiological ) intra-articular administration autologous mesenchymal stem cell ( MSCs ) patient knee osteoarthritis . Patients method Clinical trial phase I- II , randomize , multicenter , three treatment arm 10 patient group . The investigator compare intraarticular injection hialuronic acid administration two different dos mesenchymal stem cell hialuronic acid accord follow scheme : 1 . Group A : intra-articular injection hyaluronic acid ( Hyalone® ) . Single dose . 2 . Group B : Low Dosage MSCs . Intra-articular injection 10 million autologous mesenchymal progenitor stem cell culture ex - vivo ( cell suspension sterile small volume ( 5-10 ml ) vehicle suitable intraarticular injection ) follow intraarticular injection Hiaurónico Acid ( Hyalone® ) . 3 . Group C : High dose MSCs . Intra-articular injection 100 million autologous mesenchymal progenitor stem cell culture ex - vivo ( cell suspension sterile small volume ( 5-10 ml ) vehicle suitable intraarticular injection ) follow intraarticular injection Hiaurónico Acid ( Hyalone® ) . The primary endpoint safety feasibility . The investigator register occurrence complication / adverse effect study . In addition investigator assess response intra-articular infusion CMM analyze follow parameter : - Clinical assessment pain function ( Baseline , 1 , 3 , 6 12 month since treatment ) : VAS , WOMAC , KOOS , EuroQol , SF-16 , Lequesne , WOMAC , KOOS . - Radiographic ( baseline , 6 12 month since treatment ) : Femorotibial space . - Radiographic use MRI ( baseline , 6 12 month since treatment ) : assess number location lesion , cartilage thickness , signal intensity , subchondral bone alteration , volume WORMS dGEMRIC protocol .</brief_summary>
	<brief_title>Treatment Knee Osteoarthritis Intra-articular Injection Bone Marrow Mesenchymal Stem Cells</brief_title>
	<detailed_description>Purpose : To determine safety , feasibility effectiveness ( clinical radiological ) intra-articular administration autologous mesenchymal stem cell ( MSCs ) patient knee osteoarthritis . Patients method Clinical trial phase I- II , randomize , multicenter , three treatment arm 10 patient group . The investigator compare intraarticular injection hialuronic acid administration two different dos mesenchymal stem cell hialuronic acid accord follow scheme : 1 . Group A : intra-articular injection hyaluronic acid ( Hyalone® ) . Single dose . 2 . Group B : Low Dosage MSCs . Intra-articular injection 10 million autologous mesenchymal progenitor stem cell culture ex - vivo ( cell suspension sterile small volume ( 5-10 ml ) vehicle suitable intraarticular injection ) follow intraarticular injection Hiaurónico Acid ( Hyalone® ) . 3 . Group C : High dose MSCs . Intra-articular injection 100 million autologous mesenchymal progenitor stem cell culture ex - vivo ( cell suspension sterile small volume ( 5-10 ml ) vehicle suitable intraarticular injection ) follow intraarticular injection Hiaurónico Acid ( Hyalone® ) . The autologous mesenchymal stem cell obtain iliac crest culture ex vivo local anesthesia sedation . The primary endpoint safety feasibility . The investigator register occurrence complication / adverse effect study . In addition investigator assess response intra-articular infusion CMM analyze follow parameter : - Clinical assessment pain function ( Baseline , 1 , 3 , 6 12 month since treatment ) : VAS , WOMAC , KOOS , EuroQol , SF-16 , Lequesne , WOMAC , KOOS . - Radiographic ( baseline , 6 12 month since treatment ) : Femorotibial space . - Radiographic use MRI ( baseline , 6 12 month since treatment ) : assess number location lesion , cartilage thickness , signal intensity , subchondral bone alteration , volume WORMS dGEMRIC protocol . All patient meet follow inclusion exclusion criterion : Inclusion Criteria : - Males females 50 80 year old . - Diagnosis knee OA accord criterion osteoarthritis ACR ( American College Rheumatology ) . - Joint pain equal great 2.5 point visual analogue scale ( VAS ) . - Radiological Classification : Kellgren-Lawrence scale great equal 2 . - Body mass index 20 35 kg/m2 . - Ability follow study period . Exclusion Criteria : - Bilateral Osteoarthritis Knee require treatment knee . - Previous diagnosis polyarticular disease . - Severe mechanical deformation . - Arthroscopy previous 6 month . - Intraarticular infiltration hyaluronic acid last 6 month . - Systemic autoimmune rheumatic disease . - Poorly control diabetes mellitus . - Blood dyscrasia . - Immunosuppressive anticoagulant treatment . - Treatment corticosteroid 3 month prior inclusion study . - NSAID therapy within 15 day prior inclusion study . - Patients history allergy penicillin streptomycin . - Allergy hyaluronic acid poultry protein .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Males females 50 80 year old . Diagnosis knee OA accord criterion osteoarthritis ACR ( American College Rheumatology ) . Joint pain equal great 2.5 point visual analogue scale ( VAS ) . Radiological Classification : KellgrenLawrence scale great equal 2 . Body mass index 20 35 kg/m2 . Ability follow study period . Bilateral Osteoarthritis Knee require treatment knee . Previous diagnosis polyarticular disease . Severe mechanical deformation . Arthroscopy previous 6 month . Intraarticular infiltration hyaluronic acid last 6 month . Systemic autoimmune rheumatic disease . Poorly control diabetes mellitus . Blood dyscrasia . Immunosuppressive anticoagulant treatment . Treatment corticosteroids 3 month prior inclusion study . NSAID therapy within 15 day prior inclusion study . Patients history allergy penicillin streptomycin . Allergy hyaluronic acid poultry protein .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Mesenchimal stem cell</keyword>
	<keyword>Knee</keyword>
</DOC>